Twist Bioscience and Centogene have announced the launch of three next-generation sequencing (NGS) target enrichment panels to support rare disease and hereditary cancer research and diagnostics.

The new panels facilitate in-depth sequencing on target genes and reduce the need for comprehensive sequencing.

This enables sensitive detection of target genetic sequences and also provides confidence regarding the detection of variants.

Additionally, the target enrichment panels further help healthcare specialists provide precision medicine.

They are curated using the CENTOGENE Biodatabank.

Twist will synthesise the identified sequences as biotinylated capture probes that are compatible with its library preparation solution and target enrichment workflows.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Offered through Twist, the three new panels are the Twist Alliance CNTG Exome Panel, Twist Alliance CNTG Rare Disease Panel and Twist Alliance CNTG Hereditary Oncology Panel.

The Twist Alliance CNTG Exome Panel enables whole exome analysis of genetic markers that are relevant to rare diseases, while the Twist Alliance CNTG Rare Disease Panel offers focused rare-disease-related sequence analysis.

The Twist Alliance CNTG Hereditary Oncology Panel enables biomarker detection that helps indicate a high risk of cancer development.

Twist Bioscience CEO and co-founder Emily Leproust said: “Twist Alliance panels enable research by providing access to expert-developed panels tailored to specific research areas.

“As we expand our offering of Alliance panels, we believe it is critical to offer expert-developed content in an off-the-shelf format, compatible with Twist’s extended custom panel offering, enabling a wider user base for these important tools.”